Annual EBITDA:
-$272.60M-$47.61M(-21.16%)Summary
- As of today, AXSM annual EBITDA is -$272.60 million, with the most recent change of -$47.61 million (-21.16%) on December 31, 2024.
- During the last 3 years, AXSM annual EBITDA has fallen by -$147.97 million (-118.73%).
- AXSM annual EBITDA is now -14720.27% below its all-time high of -$1.84 million, reached on December 31, 2013.
Performance
AXSM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$30.51M+$12.18M(+28.52%)Summary
- As of today, AXSM quarterly EBITDA is -$30.51 million, with the most recent change of +$12.18 million (+28.52%) on September 30, 2025.
- Over the past year, AXSM quarterly EBITDA has increased by +$13.66 million (+30.92%).
- AXSM quarterly EBITDA is now -1698.37% below its all-time high of -$1.70 million, reached on September 30, 2014.
Performance
AXSM Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$186.10M+$13.66M(+6.84%)Summary
- As of today, AXSM TTM EBITDA is -$186.10 million, with the most recent change of +$13.66 million (+6.84%) on September 30, 2025.
- Over the past year, AXSM TTM EBITDA has increased by +$52.29 million (+21.93%).
- AXSM TTM EBITDA is now -10868.29% below its all-time high of -$1.70 million, reached on September 30, 2014.
Performance
AXSM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AXSM EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -21.2% | +30.9% | +21.9% |
| 3Y3 Years | -118.7% | +24.6% | -24.4% |
| 5Y5 Years | -306.5% | -44.5% | -94.3% |
AXSM EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -118.7% | at low | -569.1% | +58.8% | -35.3% | +26.9% |
| 5Y | 5-Year | -306.5% | at low | -569.1% | +58.8% | -97.0% | +26.9% |
| All-Time | All-Time | >-9999.0% | at low | -1698.4% | +58.8% | >-9999.0% | +26.9% |
AXSM EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$30.51M(+28.5%) | -$186.10M(+6.8%) |
| Jun 2025 | - | -$42.69M(+20.0%) | -$199.76M(+13.6%) |
| Mar 2025 | - | -$53.34M(+10.4%) | -$231.10M(+5.5%) |
| Dec 2024 | -$272.60M(-21.2%) | -$59.56M(-34.8%) | -$244.62M(-2.6%) |
| Sep 2024 | - | -$44.17M(+40.3%) | -$238.39M(+6.3%) |
| Jun 2024 | - | -$74.03M(-10.7%) | -$254.43M(-7.2%) |
| Mar 2024 | - | -$66.86M(-25.4%) | -$237.25M(-35.6%) |
| Dec 2023 | -$224.99M(-28.3%) | -$53.33M(+11.4%) | -$174.96M(+0.2%) |
| Sep 2023 | - | -$60.21M(-5.9%) | -$175.33M(-12.7%) |
| Jun 2023 | - | -$56.86M(-1146.9%) | -$155.61M(-13.2%) |
| Mar 2023 | - | -$4.56M(+91.5%) | -$137.52M(+19.5%) |
| Dec 2022 | -$175.40M(-40.7%) | -$53.70M(-32.6%) | -$170.94M(-14.3%) |
| Sep 2022 | - | -$40.49M(-4.4%) | -$149.54M(-5.2%) |
| Jun 2022 | - | -$38.77M(-2.1%) | -$142.15M(-6.1%) |
| Mar 2022 | - | -$37.98M(-17.6%) | -$133.96M(-8.2%) |
| Dec 2021 | -$124.63M(-24.3%) | -$32.30M(+2.4%) | -$123.81M(-3.8%) |
| Sep 2021 | - | -$33.11M(-8.3%) | -$119.25M(-11.2%) |
| Jun 2021 | - | -$30.57M(-9.8%) | -$107.26M(-13.5%) |
| Mar 2021 | - | -$27.84M(-0.4%) | -$94.47M(+4.7%) |
| Dec 2020 | -$100.26M(-49.5%) | -$27.74M(-31.3%) | -$99.12M(-3.5%) |
| Sep 2020 | - | -$21.12M(-18.8%) | -$95.80M(-2.3%) |
| Jun 2020 | - | -$17.77M(+45.3%) | -$93.62M(-4.9%) |
| Mar 2020 | - | -$32.49M(-33.0%) | -$89.28M(-32.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$67.07M(-125.1%) | -$24.42M(-29.0%) | -$67.21M(-28.7%) |
| Sep 2019 | - | -$18.94M(-40.9%) | -$52.22M(-25.8%) |
| Jun 2019 | - | -$13.44M(-29.1%) | -$41.52M(-15.1%) |
| Mar 2019 | - | -$10.41M(-10.3%) | -$36.06M(-9.9%) |
| Dec 2018 | -$29.79M(-8.1%) | -$9.44M(-14.7%) | -$32.80M(-10.1%) |
| Sep 2018 | - | -$8.23M(-3.2%) | -$29.79M(-7.0%) |
| Jun 2018 | - | -$7.98M(-11.6%) | -$27.85M(-4.7%) |
| Mar 2018 | - | -$7.15M(-11.2%) | -$26.61M(+1.9%) |
| Dec 2017 | -$27.56M(-1.9%) | -$6.43M(-2.3%) | -$27.12M(+4.2%) |
| Sep 2017 | - | -$6.29M(+6.7%) | -$28.30M(+3.1%) |
| Jun 2017 | - | -$6.74M(+12.0%) | -$29.22M(+0.3%) |
| Mar 2017 | - | -$7.66M(-0.6%) | -$29.30M(-6.5%) |
| Dec 2016 | -$27.05M(-135.8%) | -$7.62M(-5.7%) | -$27.52M(-8.6%) |
| Sep 2016 | - | -$7.20M(-5.5%) | -$25.34M(-25.7%) |
| Jun 2016 | - | -$6.82M(-16.0%) | -$20.16M(-30.7%) |
| Mar 2016 | - | -$5.88M(-8.3%) | -$15.42M(-33.5%) |
| Dec 2015 | -$11.47M(-109.0%) | -$5.43M(-168.5%) | -$11.55M(-43.2%) |
| Sep 2015 | - | -$2.02M(+2.9%) | -$8.07M(-4.2%) |
| Jun 2015 | - | -$2.08M(-3.6%) | -$7.74M(-36.8%) |
| Mar 2015 | - | -$2.01M(-3.2%) | -$5.66M(-55.2%) |
| Dec 2014 | -$5.49M(-198.4%) | -$1.95M(-14.8%) | -$3.65M(-114.8%) |
| Sep 2014 | - | -$1.70M | -$1.70M |
| Dec 2013 | -$1.84M | - | - |
FAQ
- What is Axsome Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Axsome Therapeutics, Inc.?
- What is Axsome Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Axsome Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Axsome Therapeutics, Inc.?
- What is Axsome Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Axsome Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Axsome Therapeutics, Inc.?
- What is Axsome Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Axsome Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of AXSM is -$272.60M
What is the all-time high annual EBITDA for Axsome Therapeutics, Inc.?
Axsome Therapeutics, Inc. all-time high annual EBITDA is -$1.84M
What is Axsome Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, AXSM annual EBITDA has changed by -$47.61M (-21.16%)
What is Axsome Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of AXSM is -$30.51M
What is the all-time high quarterly EBITDA for Axsome Therapeutics, Inc.?
Axsome Therapeutics, Inc. all-time high quarterly EBITDA is -$1.70M
What is Axsome Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, AXSM quarterly EBITDA has changed by +$13.66M (+30.92%)
What is Axsome Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of AXSM is -$186.10M
What is the all-time high TTM EBITDA for Axsome Therapeutics, Inc.?
Axsome Therapeutics, Inc. all-time high TTM EBITDA is -$1.70M
What is Axsome Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, AXSM TTM EBITDA has changed by +$52.29M (+21.93%)